X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NTC and I-MED Pharma’s successful collaboration to bring I-DEFENSE® innovative ophthalmic ointment first to Canada and now to the U.S.A. is a testament to the dedication of both companies to advancing the science of dry eye.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: I-Defense
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: I-MED
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 15, 2021
Details:
NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for post-cataract surgery.
Lead Product(s): Levofloxacin,Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
